We propose that prevention of metastatic progression using a neoadjuvant treatment protocol could be more efficacious and provide a greater survival benefit to HER2+ve breast cancer patients than late intervention, particularly against the development of difficult to treat brain metastases. This evidence concerns the gene ERBB2 and breast cancer.